Literature DB >> 1356030

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.

A R Hanauske1, D Degen, S G Hilsenbeck, M C Bissery, D D Von Hoff.   

Abstract

Taxotere (RP 56976, NSC 628503) is a new semisynthetic analog of taxol (NSC 125973) with promising antitumor activity in a variety of preclinical screening systems. Clinical responses after treatment with taxol have been observed in ovarian cancer, breast, lung cancer and melanoma. Both agents act through induction of microtubule polymerization. We have studied and compared the antiproliferative action of Taxotere and taxol against a variety of freshly explanted human tumor specimens using an in vitro soft agar cloning system. Final concentrations of 0.025-10 micrograms/ml were used for both agents in short-term (1 h) or continuous (14 days) incubations. Taxotere was studied using a 1 h incubation in a total of 167 tumor specimens of which 85 (51%) were evaluable. At 10 micrograms/ml, Taxotere inhibited 32 out of 78 (41%) specimens (colony formation less than or equal to 0.5 x control). Cytotoxicity of Taxotere was observed against breast, lung, ovarian, colorectal cancer and melanoma tumor colony forming units. For comparison, 227 specimens were exposed to taxol for 1 h. At 10 micrograms/ml, 32 out of 97 evaluable specimens (33%) were significantly inhibited. Cytotoxicity was observed against breast, lung, ovarian, colorectal cancer and melanoma tumor colony forming units. In head-to-head comparisons, 29 specimens were found more sensitive to Taxotere than taxol, while only 13 were more sensitive to taxol than to Taxotere. These data indicate that cross-resistance between the two agents is incomplete and that on a concentration basis Taxotere is more cytotoxic than taxol in the majority of human primary tumor specimens evaluated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356030     DOI: 10.1097/00001813-199204000-00008

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  17 in total

1.  Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS).

Authors:  Yi-Dong Yan; Nirmal Marasini; Young Keun Choi; Jong Oh Kim; Jong Soo Woo; Chul Soon Yong; Han Gon Choi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-27       Impact factor: 2.441

Review 2.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines.

Authors:  Satoshi Tabuchi; Soji Ozawa; Kazuo Koyanagi; Naoyuki Shigematsu; Atsushi Kubo; Masakazu Ueda; Yuko Kitagawa; Masaki Kitajima
Journal:  Exp Ther Med       Date:  2011-05-10       Impact factor: 2.447

4.  Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression.

Authors:  Leticia Medina-Gundrum; Cesario Cerna; Lionel Gomez; Elzbieta Izbicka
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

5.  Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

6.  Impact of MAGE-A antigens on taxane response in oral squamous cell carcinoma.

Authors:  Urs D A Müller-Richter; Albert Dowejko; Oliver Driemel; Tobias Reuther; Torsten E Reichert; Alexander C Kübler
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

7.  Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.

Authors:  B T Hill; R D Whelan; S A Shellard; S McClean; L K Hosking
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 8.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

9.  An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.

Authors:  Agnes Benedict; David A Cameron; Hélène Corson; Stephen E Jones
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Docetaxel: an alternative taxane in ovarian cancer.

Authors:  N Katsumata
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.